Summer 2026

Data Analytics Intern

Posted on 5/16/2026

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$30 - $35/hr

San Carlos, CA, USA

Hybrid

In-person role; expected to be in-office weekly Tue/Wed at San Carlos (other days as needed).

Category
Data & Analytics (1)
Required Skills
LLM
Redshift
FastAPI
Python
SQL
OpenAI
AWS
REST APIs
Flask
Databricks
Requirements
  • Actively enrolled in a university undergraduate degree program (entering junior year or above preferred; with a 3.0 GPA) or enrolled in master's or PhD Program; Currently pursuing a degree in Computer Science, Data Science, Artificial Intelligence, or related field
  • Understanding of relational databases, data warehousing, machine learning, data modeling concepts (star schema, fact/dimension tables)
  • Hands-on experience on Databricks
  • Strong knowledge in Amazon Web Services, Redshift, SQL (query optimization, joins, aggregations, common table expressions)
  • Basic experience with Python
  • Familiarity with REST APIs, Artificial Intelligence/LLMs and prompt engineering
  • Interest in AI/LLMs and prompt engineering
  • Familiarity with LLM APIs (e.g., OpenAI)
Responsibilities
  • AI Bot Development: Assist in designing and building an AI-powered chatbot interface for querying Redshift data
  • AI Bot Development: Implement NL2SQL pipelines (Natural Language to SQL) to translate user prompts into executable code
  • AI Bot Development: Metadata Management: Create and maintain table/column descriptions within Redshift to provide the LLM with necessary context
  • AI Bot Development: Prompt Engineering: Build and test evaluation pipelines to ensure generated SQL is accurate and functional
  • Data Engineering & Redshift Optimization: Schema Interpretation: Understand Redshift data models and create comprehensive metadata/documentation to feed into the AI context
  • Data Engineering & Redshift Optimization: Query Guardrails: Write and optimize SQL queries while implementing logic to prevent "expensive" or "destructive" queries
  • Data Engineering & Redshift Optimization: Performance Tuning: Support data transformations and create views/materialized views to simplify the data structure for the AI Input
  • Backend & AWS Integration: Service Development: Build Python-based backend services (FastAPI/Flask) to handle the flow between the UI, the LLM, and Redshift
  • Backend & AWS Integration: Secure Execution: Handle authentication and secure query execution
  • Backend & AWS Integration: Cloud Infrastructure: Work with AWS services including: AWS Lambda for serverless execution; Amazon Bedrock (or SageMaker) for accessing LLMs; AWS Secrets Manager for secure Redshift credential handling; Microsoft Outlook Integration with AWS
Desired Qualifications
  • None

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Brukinsa generated $1.1 billion in first-quarter 2026 sales, up 38%.
  • Sonrotoclax won FDA accelerated approval for relapsed or refractory mantle cell lymphoma.
  • TEVIMBRA plus ZIIHERA holds FDA Priority Review for HER2-positive gastric cancer.

What critics are saying

  • Revenue remains heavily dependent on Brukinsa, exposing BeOne to competitive erosion.
  • Sonrotoclax's approval depends on CELESTIAL-RRMCL confirmatory results.
  • TEVIMBRA diversification is unproven, with revenue still trailing Brukinsa materially.

What makes BeOne unique

  • BeOne combines Brukinsa, Tevimbra, and sonrotoclax across blood and solid tumors.
  • Its global trial network spans 30,000 patients and 75 approval markets.
  • Brukinsa remains the only BTK inhibitor with head-to-head PFS superiority.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at BeOne who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

-16%

1 year growth

-19%

2 year growth

-13%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...

INACTIVE